{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Cogent Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"COGT"},"Address":{"label":"Address","value":"200 CAMBRIDGE PARK DRIVE,SUITE 2500 3RD FLOOR, CAMBRIDGE, Massachusetts, 02140, United States"},"Phone":{"label":"Phone","value":"+1 617 945-5576"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling."},"CompanyUrl":{"label":"Company Url","value":"https://www.cogentbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andrew R. Robbins","title":"President, Chief Executive Officer & Director"},{"name":"Brad Barnett","title":"Chief Technology Officer"},{"name":"Jessica Sachs","title":"Chief Medical Officer"},{"name":"John Edward Robinson","title":"Chief Scientific Officer"},{"name":"Rachael Z. Easton","title":"Vice President & Head-Clinical Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}